TRIPLE NEGATIVE BREAST NEOPLASMS

This study tested whether a combination of olaparib (a targeted therapy) and pembrolizumab (an immunotherapy) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that initially responded to chemo-immunotherapy. The tri…

This Phase 3 trial tested whether the immunotherapy drug avelumab, given after standard treatments like surgery and chemotherapy, can help prevent breast cancer from coming back in people with high-risk triple negative breast cancer. The study enrolled 474 participants who had al…

This study tested a combination of two drugs, ladiratuzumab vedotin and pembrolizumab, in 185 people with advanced triple-negative breast cancer that had spread. The main goals were to check for side effects and see how well the drugs shrank tumors. The trial was completed and pr…

This phase 3 trial tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with triple-negative breast cancer that has returned within 12 months of initial treatment. The study enrolled 595 participants and compared survival outcomes betwee…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps people with triple negative breast cancer. Over 1,100 participants received either pembrolizumab or a placebo with chemo before surgery, then continued the study drug after surgery. The goal wa…

This early-phase trial tested an experimental drug called TAK-676 combined with the immunotherapy pembrolizumab after radiation therapy in 34 adults with advanced lung, breast, or head/neck cancers that had stopped responding to checkpoint inhibitors. The main goals were to check…